 Welcome traders to another Tick-Nail earnings report preview with me, Patrick Munley. Before we jump into today's report, as always it's important we adhere to the risk disclaimer. The material provided is for information purposes only and should not be considered as investment advice. The views, information and opinions expressed by me in this recording are solely mine and they're not indicative or representative. Those held by Tick-Nail UK or Tick-Nail Europe Limited. Okay, let's jump into today's report. We're looking at Biontech who reports before the US Open today. Consensus is looking for an earnings per share print of $9.14 on revenue of $4.59 billion. Biontech last issued its earnings data on March 30th. The reported $12.18 per share for the quarter. Topping analyst consensus estimates for $7.44 by $4.74 cents. The business had revenue of $5.53 billion for the quarter compared to analysts expectations of $3.83 billion. So revenue for the quarter was up 1,501% on a year-over-year basis. Biontech has generated $46.76 earnings per share over the last year. On a diluted earnings per share basis that comes in at $46.76. And currently it has a price-to-earnings ratio of 2.9. Earnings for Biontech are expected to decrease by 53.76% over the coming year from $34.60 to $16 per share. Biontech has confirmed that its next quarterly earnings report will be published there before the bell looking for a release there at 8 a.m. Eastern time. Okay, let's look at some of the statistical trading patterns around the earnings releases. Prantic shares have moved higher in the immediate aftermath of earnings. Six out of 10 of the previous reports on average the stock moved up 2.4% in the first day of trading after the company's release. Based on the previous 10 earnings releases, Biontech is more likely to trade lower one day after earnings for an average loss of 1.5%. On average, Biontech stock has moved lower one week after earnings for an average loss of 4.3%. In terms of what the option market is pricing, options traders are looking for a 10.8% move on earnings. The stock has averaged an 8.3% move in recent quarters. From the flow and sentiment perspective, Friday March 25th, there was a notable buy of 581 contracts of the $135 pull-ups expiring January 19th, 2024. Options order flow there in general has been more bullish. Investor sentiment going into the company's earnings release has 52% expecting earnings. Beat consensus estimates for year every year earnings growth of 72.78% with revenue increasing by 85.89%. Short interest has decreased by 21.1% since the company's last earnings release, although the stock has drifted lower by 26.2% from its open following the earnings release to be 44% below its 200-day living average of $243.10. Let's jump into the chart and see where there may be some opportunities from a trading perspective. If we look at the Biontech chart, obviously it's been a fairly significant downtrend. However, I do note here on the daily timeframe a potential inverse heading shoulders pattern developing. Obviously, we would need to see some upside in terms of earnings per share there to get a move back through this descending trend line of $151. If we could get that move and a close through there on a daily closing basis, then I would look for a move up into projected monthly range resistance $181.54 and notably we have a gap just above the $194 level. However, if we get back down through these prior lows at the $121 handle, I would be bearish in looking for a move lower to test the high volume load here at the $105.50 and we also have monthly projected range support coming in there just below $104.50. Key levels for me are going to be that $121 level to the downside a break and I want to be short to the upside through $151. I want to be long tucking move up into the monthly projected range resistance. As always, trade us plan the trade, trade the plan and most importantly manage your risk. Until next time, thanks very much.